Commentary By: Josh Olstein, PGY-3
Earlier this month the FDA approved Tekturna (aliskiren) the first drug in a novel class of antihypertensives that work by directly inhibiting renin. While Novartis has yet to release pricing information, don’t expect to see this …
Commentary by Cara Litvin, PGY-3
The results of one of the more remarkable studies from the meeting of the American College of Cardiology were presented on Monday, along with the simultaneous early publishing of the study online in the New England Journal of …
It seemed to be a slow week in the medical literature, but that will likely change as the 2007 American College of Cardiology Scientific Session is now underway. Theheart.org has an excellent summary about what to expect from the meetings. …
Consultant: Robert Raicht, MD Professor of Medicine, Chief Division of Gastroenterology
Clinical Vignette:
The patient is a 50 year old male with a past medical history notable for type II diabetes, hypertension and recently treated right foot cellulitis and c.difficile colitis who …
The debate about the ethically questionable relationship between physicians and the pharmaceutical industry opened up again this morning on the front page of the New York Times. Although the article is heavy on interview and anecdote and a little short on …
Commentary By Sandra D’Angelo, PGY-3
Breast cancer is the most common cancer diagnosed in women, second only to lung cancer as a leading cause of death from cancer. Experts state that approximately 210, 000 women will be diagnosed in …
Welcome to ShortCuts, yet another new feature of Clinical Correlations. Every week we will post what we feelare the 5 most interesting articles from the news and literature with links. We’re not attempting to digest any of this for you or to …
Coming right on the heels of the recent warning from the FDA about the risk of fractures and Rosiglitazone, the FDA announced on March 9th that pioglitazone (Actos) has also been linked to an increased occurrence of arm, hand, and foot fractures …